ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with...

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), is used for type 2 diabetes (T2D).
• Real-world effectiveness data are crucial for understanding treatment outcomes beyond clinical trials.

Purpose of the Study:

• To evaluate the real-world effectiveness of dulaglutide in T2D patients.
• To assess glycemic control and body weight changes over 24 months.
• To examine the durability of dulaglutide's treatment effects.

Main Methods:

• A multicenter, prospective, observational study (ANDREW) was conducted.
• 1584 T2D patients initiated once-weekly dulaglutide (0.75 or 1.5 mg).
• Data were collected on glycemic control (HbA1c, FPG) and weight parameters up to 24 months.

Main Results:

• At 12 months, significant reductions in HbA1c (-10 mmol/mol), FPG (-24.9 mg/dL), body weight (-3.4 kg), and waist circumference (-3.3 cm) were observed (p < 0.0001).
• Among patients completing 24 months (n=270), initial improvements in HbA1c and FPG stabilized after 12 months.
• Treatment discontinuation occurred in 170 patients before the 12-month endpoint.

Conclusions:

• Dulaglutide is an effective treatment for T2D, demonstrating significant improvements in glycemic control and body weight in real-world settings.
• The study confirms findings from randomized controlled trials regarding the metabolic and weight-related benefits of dulaglutide.
• Sustained benefits require ongoing patient support for lifestyle modifications alongside GLP-1RA therapy.